Big Take23 Joulu 2022

Declining ALS Patients Are Waiting On The FDA's Next Move

For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon and especially insidious form of ALS that runs in families. Patients are urging the US Food and Drug Administration to speed access to the drug, which hasn’t yet been approved because clinical trials didn’t conclusively show it works.

As pharmaceutical companies use new technologies to seek cures of all kinds, this tension between making sure drugs are effective and safe, and offering not-quite-ready but possibly life-saving treatment to people for whom it’s now or never, is becoming more acute.

Bloomberg’s chief medical writer Robert Langreth joins this episode to talk about the race to find a treatment for ALS–and the back and forth between patients, companies and government regulators. We also hear the story of a Pennsylvania family that has passed on a gene for ALS from generation to generation–and their demands for access to the new treatment.

Learn more about the episode here: https://bloom.bg/3WIkvCm

Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK

Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.

See omnystudio.com/listener for privacy information.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(1016)

The Steamy, Billion-Dollar World of Romantasy

Romantasy books have created a near-billion-dollar industry in the US alone. This week, fans are racing to grab a copy of Rebecca Yarros’ Threshing Day, and bracing for the sixth installment of one of...

2 Loka 18min

Man City Scandal Threatens UK-UAE Ties

The Premier League has found its top-ranked club, the star-studded and highly decorated Manchester City, guilty of artificially boosting financial results by more than £900 million over nine years. Th...

1 Loka 16min

Can $700 Million Buy Republicans the US Senate?

The 2026 midterms are on track to become the most expensive elections in US history, with Republican Senate candidates raking in hundreds of millions from PACs and Democrats riding a growing wave of i...

30 Syys 16min

China’s New Message to Its Billionaires: Pay Up

China is ramping up an ongoing effort to shore up local government budgets and fund AI data centers with tax revenue from its richest citizens. Billionaires across the country are seeing bills hit the...

29 Syys 13min

Could Bond Yields Break the Stock Market?

At over 5%, the 10-year Treasury yield is the highest since 2007. Those soaring yields are raising lots of questions about whether investors should be trimming stocks and buying bonds. But timing such...

28 Syys 17min

Weekend Listen: There's a Mind-Boggling Number of Rich People in America

In 2014, the economists Owen Zidar and Eric Zwick were asked by the US Treasury to conduct a study on the tax burden of private business owners. One of their central findings is that there are about t...

27 Syys 59min

Crafting America’s Favorite Countertops Is Killing Workers

People who fabricate artificial stone are getting sick with a deadly chronic illness—on that, there’s no debate. But whether it’s the individual shops or the material’s manufacturers who should be hel...

25 Syys 21min

This Isn’t Your Grandparents’ UN

At this week’s UN General Assembly meeting in New York, an AI executive delivered dire warnings via video. President Trump threatened to annihilate Iran. China’s Xi Jinping skipped the meeting altoget...

24 Syys 15min